PLD
56
8
DNB
82
4
ADBE
49
3
VTR
47
-7
SIG
52
3
EQT
57
-2
LB
63
22
ROK
62
15
FLR
58
3
APD
59
2
GT
62
6
HPQ
63
6
PNC
64
4
MHK
49
4
DFS
64
2
EXC
53
-3
BBY
46
10
GOOGL
40
-5
AA
48
-12
PSA
58
2
PLD
56
8
DNB
82
4
ADBE
49
3
VTR
47
-7
SIG
52
3
EQT
57
-2
LB
63
22
ROK
62
15
FLR
58
3
APD
59
2
GT
62
6
HPQ
63
6
PNC
64
4
MHK
49
4
DFS
64
2
EXC
53
-3
BBY
46
10
GOOGL
40
-5
AA
48
-12
PSA
58
2
Financhill
Back

Kymera Therapeutics 10K Form

Buy
62

KYMR
Kymera Therapeutics

Last Price:
44.98
Seasonality Move:
21.35%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive KYMR News And Ratings

See the #1 stock for the next 7 days that we like better than KYMR

KYMR Financial Statistics

Sales & Book Value

Annual Sales: $78.59M
Cash Flow: $-50M
Price / Cash Flow: 0
Annual Sales: $13.79
Price / Book: 3.26

Profitability

EPS (TTM): -2.34000
Net Income (TTM): $-167.47M
Gross Margin: --
Return on Equity: -27.19%
Return on Assets: -21.71%

Kymera Therapeutics Earnings Forecast

Key Kymera Therapeutics Financial Ratios

  • The Research & Development expenses have been 240.59% of Revenue.
  • The Interest Expense is -0.13% of Operating Income.
  • The Net Earning history of KYMR is -186.99% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 2 years.

Kymera Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: KYMR
Website: kymeratx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 8.55
Quick Ratio: 8.29

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

KYMR Technical Analysis vs Fundamental Analysis

Buy
62
Kymera Therapeutics (KYMR) is a Buy

Is Kymera Therapeutics a Buy or a Sell?